Press Releases
Date Title and Summary View
Jun 20, 2016 SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC. Retrophin intends to file a New Drug Application with the U.S. Food and Drug Administrat...
May 26, 2016 SAN DIEGO, May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences: Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9, 2016 at 2:30 p.m. ET JMP Securities Life Sciences Conference in New Yo...
May 3, 2016 First quarter revenues increased 67 percent year-over-year Enrollment of the Phase 2 DUET study of sparsentan completed; top-line results expected third quarter 2016 SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2016 financial results. Net product sales for the first quarter 2016...
Apr 21, 2016 SAN DIEGO, April 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Deutsche Bank 41st Annual Health Care Conference in Boston on Thursday, May 5, 2016 at 2:10 p.m. ET.   A live webcast of the presentation will be available at http://ir.retrophin.com/e...
Apr 19, 2016 SAN DIEGO, April 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2016 financial results on Tuesday, May 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p....
Apr 4, 2016 SAN DIEGO, April 04, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Gary A. Lyons will become the Company's next independent Chairman of the Board of Directors, effective at the conclusion of the annual meeting of stockholders, to be held on May 18, 2016. Mr. Lyons, an independent director of Retrophin since 2014, will suc...
Mar 30, 2016 SAN DIEGO, March 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the Company has completed enrollment of the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an approved pharmacological treatment option that often leads to end-stage renal dis...
Mar 24, 2016 SAN DIEGO, March 24, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that four abstracts related to the development of RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), have been accepted for poster presentation at the 20th International Congress of ...
Mar 9, 2016 SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced new data supporting further clinical development of RE-024, the Company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic disorder with no approved treatments. Key f...
Mar 3, 2016 SAN DIEGO, March 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Thursday, March 17, 2016 at 1:35 p.m. ET.   A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase